These stocks have jumped in the double- and triple-digits.

Wall Street expects sales to soar as several commercial launches approach.

Morgan Stanley says U.S. equity-market leadership is beginning to expand beyond the semiconductor and AI infrastructure ...

Morgan Stanley said the recent weakness in U.S. semiconductor stocks is a sign that the market gains are broadening, with ...

Morgan Stanley’s pivot is from “chip winners” to hyperscalers with AI infrastructure optionality. MSFT has the strongest mix ...

The deal values Crinetics at $85 per share in cash, representing a potential upside of about 100% from the stock’s closing ...

Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant ...

Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...

One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

Mr Wilson’s interest rate outlook is central to his broader call. Falling energy prices, fading tariff-related inflation and ...

Moderna's growth story is just beginning.